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Objectives: Outcomes after carotid endarterectomy
(CEA) and carotid angioplasty and stenting (CAS) from
the Society for Vascular Surgery Vascular Registry (SVS-
VR) were ﬁrst reported in 2008. We present an updated
report on 30-day outcomes from the complete database.
Methods: There were 9865 procedures by 370 pro-
viders at 80 sites on 6492 CEA patients and 3373 CAS pa-
tients. The primary end point (major adverse coronary
event [MACE]) was a composite of death, stroke, and
myocardial infarction (MI) at 30 days.
Results: There were no statistically signiﬁcant differ-
ences in age or gender between CEA and CAS patients.
A total of 98.6% of CEA and 72.0% of CAS were treated
for atherosclerotic (ATH) disease. CAS patients were also
treated for restenosis (23.3%) and radiation (4.8%). CAS
patients were more likely to be symptomatic (45.4% vs
37.8%), with a higher prevalence of high-risk factors.
CAS patients had statistically signiﬁcant higher (P <
.0001) rates of MACE (6.76% vs 4.07%), stroke (4.77%
vs 2.53%), and mortality (1.84% vs 0.86%), but not MI
(1.30% vs 1.22%). The differences remained signiﬁcant af-
ter stratiﬁcation by symptomatology and multivariate logis-
tic regression analysis (Table).
Conclusions: An updated analysis using a large real-
world, multispecialty database demonstrated that CAS
was associated with higher rates of death and stroke
compared with CEA, even after controlling for differences
in these unmatched groups.Table. Unadjusted and adjusted odds ratios (OR) comparing
endarterectomy (CEA)
CAS (vs CEA) Unadjusted
Outcome Group OR 95% CI
Death/stroke/MI Entire cohort 1.71 1.43-2.05
Symptomatic 1.62 1.27-2.07
Asymptomatic 1.65 1.26-2.17
Stroke Entire cohort 1.93 1.55-2.41
Symptomatic 1.68 1.26-2.23
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Objectives: Spinal cord ischemia (SCI) is a devas-
tating, but potentially preventable complication of thoracic
endovascular aortic repair (TEVAR). The purpose of this
analysis was to determine what factors predict SCI after
TEVAR.
Methods: All TEVAR patients at a single institution
were reviewed for demographics, comorbidities, anatomic
centerline analysis, and procedural characteristics. A step-
wise-elimination logistic regression algorithm was used
and the model bootstrapped 1000 times to derive the
best subset of independent predictors.
Results: From 2002 to 2013, 741 patients under-
went TEVAR for various indications and 68 (9.2%)
developed SCI, which was permanent in 38 (5.1%).end points in carotid artery stenting (CAS) and carotid
OR Adjusted OR
P OR 95% CI P
<.0001 1.36 1.11-1.66 .0031
.0001 1.33 1.01-1.75 .0437
.0003 1.40 1.04-1.88 .0271
<.0001 1.64 1.29-2.08 <.0001
.0004 1.50 1.10-2.05 .0113
<.0001 1.80 1.23-2.63 .0024
